Dose Insider / Glossary / Albiglutide

AlbiglutideWhat it was and what the Harmony Outcomes trial showed

Updated November 20, 2026 · 3 min read · Harmony Outcomes (Lancet 2018), Federal Register 2016, Nauck 2021, DailyMed

Albiglutide is a GLP-1 receptor agonist that was injected once a week for type 2 diabetes and sold as Tanzeum, approved by the FDA on April 15, 2014.

4.6Albiglutide, heart events, Harmony Outcomes
Heart events, Harmony OutcomesPer 100 person-years, type 2 diabetesAlbiglutide4.6Placebo5.9Heart events, HarmonyOutcomesPer 100 person-years, type 2 diabetesAlbiglutide4.6Placebo5.9

Hazard ratio 0.78 over a median of 1.6 years.

On this page

Its cardiovascular trial, Harmony Outcomes, found fewer heart attacks, strokes and cardiovascular deaths than on placebo. We found no current label for it on DailyMed on November 20, 2026.1,2,3,4

What it was

A 2021 review by Michael Nauck and colleagues groups albiglutide with the long-acting GLP-1 medicines, together with liraglutide, weekly exenatide, dulaglutide and semaglutide. It notes that these have stronger effects on overnight and fasting blood sugar and on HbA1c than the short-acting ones.3 In Harmony Outcomes it was given at 30 to 50 mg once a week, depending on blood sugar response and tolerability.1

The FDA's notice on its patent review gives the approval date of the biologic product Tanzeum as April 15, 2014.2 A search of DailyMed, the U.S. database of current drug labels, returns nothing for albiglutide, so there is no label to read today.4

The Harmony Outcomes trial

Harmony Outcomes enrolled 9,463 adults aged 40 or older with type 2 diabetes and cardiovascular disease, at 610 sites in 28 countries. They were assigned in equal numbers, 4,731 and 4,732, to albiglutide or placebo, on top of usual care, and followed for a median of 1.6 years.1

The trial was funded by GlaxoSmithKline, the maker.1

Its length was set by events, not by the calendar. Screening ran from July 2015 to November 2016. On November 8, 2017, the investigators determined that 611 primary events and a median follow-up of at least 1.5 years had been reached. Participants then came back for a final visit and stopped the study drug; the last visit was on March 12, 2018.1 Event-driven trials work this way so that they stop once they hold enough events to answer the question, which is why this one ran for about a third of the time REWIND did.

The safety signals it checked

The trial report also counted three events often raised about GLP-1 medicines. Acute pancreatitis occurred in 10 people on albiglutide and 7 on placebo, pancreatic cancer in 6 and 5, and medullary thyroid carcinoma in none in either group.1 In a trial of this size and length those counts are too small to settle the questions, but they did not show a clear excess.

Among the heart trials

Harmony Outcomes belongs to a series of cardiovascular trials of GLP-1 medicines that used the same three-part outcome. LEADER, for liraglutide, found 13.0% against 14.9% over a median of 3.5 years, a hazard ratio of 0.87.5 REWIND, for dulaglutide, found 12.0% against 13.4% over 5.4 years, a hazard ratio of 0.88.6 Albiglutide's hazard ratio of 0.78 came from a shorter trial, which is one reason the percentages are smaller in every group.

What it means today

Albiglutide matters now mostly as evidence: it added another trial in which a GLP-1 medicine lowered cardiovascular risk in people with type 2 diabetes and heart disease. People who were on Tanzeum have other weekly options among the medicines with current labels, such as Ozempic, Trulicity and Mounjaro. Our page on Ozempic and Mounjaro compares the two most used.

Sources

  1. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-1529. Funded by GlaxoSmithKline. doi:10.1016/S0140-6736(18)32261-X
  2. Food and Drug Administration. Determination of regulatory review period for purposes of patent extension; TANZEUM. Federal Register, June 10, 2016, document 2016-13797. federalregister.gov
  3. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
  4. DailyMed, U.S. National Library of Medicine. Search for "albiglutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
  5. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published November 17, 2025; section 14. dailymed.nlm.nih.gov
  6. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; section 14.5. dailymed.nlm.nih.gov

Related analyses

Log any GLP-1 medicine you take and see your doses, weight and symptoms together.

Open Dose Insider